ATE256186T1 - Verwendungen von angiogenischer factor vegf145 in der behandlung von kardiovaskulaeren krankheiten - Google Patents

Verwendungen von angiogenischer factor vegf145 in der behandlung von kardiovaskulaeren krankheiten

Info

Publication number
ATE256186T1
ATE256186T1 AT97940771T AT97940771T ATE256186T1 AT E256186 T1 ATE256186 T1 AT E256186T1 AT 97940771 T AT97940771 T AT 97940771T AT 97940771 T AT97940771 T AT 97940771T AT E256186 T1 ATE256186 T1 AT E256186T1
Authority
AT
Austria
Prior art keywords
vegf145
derivatives
novel
protein products
vegf
Prior art date
Application number
AT97940771T
Other languages
English (en)
Inventor
Gera Neufeld
Eli Keshet
Israel Vlodavsky
Zoya Poltorak
Original Assignee
Technion Res & Dev Co Ltd
Collateral Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Res & Dev Co Ltd, Collateral Therapeutics filed Critical Technion Res & Dev Co Ltd
Application granted granted Critical
Publication of ATE256186T1 publication Critical patent/ATE256186T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT97940771T 1996-09-06 1997-09-04 Verwendungen von angiogenischer factor vegf145 in der behandlung von kardiovaskulaeren krankheiten ATE256186T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2553796P 1996-09-06 1996-09-06
US08/784,551 US6013780A (en) 1996-09-06 1997-01-21 VEGF145 expression vectors
PCT/US1997/015471 WO1998010071A1 (en) 1996-09-06 1997-09-04 Angiogenic factor and use thereof in treating cardiovascular disease

Publications (1)

Publication Number Publication Date
ATE256186T1 true ATE256186T1 (de) 2003-12-15

Family

ID=26699889

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97940771T ATE256186T1 (de) 1996-09-06 1997-09-04 Verwendungen von angiogenischer factor vegf145 in der behandlung von kardiovaskulaeren krankheiten

Country Status (14)

Country Link
US (3) US6013780A (de)
EP (1) EP0925360B1 (de)
JP (1) JP2001500728A (de)
KR (1) KR20000068506A (de)
CN (1) CN1236390A (de)
AT (1) ATE256186T1 (de)
AU (1) AU737898B2 (de)
CA (1) CA2265252C (de)
DE (1) DE69726741T2 (de)
EA (1) EA004646B1 (de)
ES (1) ES2212127T3 (de)
IL (1) IL128727A (de)
NZ (1) NZ334508A (de)
WO (1) WO1998010071A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238673B2 (en) 1989-03-31 2007-07-03 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US20040071637A1 (en) * 1993-04-27 2004-04-15 Elia James P. Method for repairing a damaged portion of a human organ
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
US20030165467A1 (en) * 1997-01-21 2003-09-04 Technion Research & Development Co., Ltd. Angiogenic factor and use thereof in treating cardiovascular disease
US6485942B1 (en) 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
US6376471B1 (en) * 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
SG117417A1 (en) * 1998-02-06 2005-12-29 Collateral Therpeutics Inc Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US6958147B1 (en) * 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
WO2000024412A2 (en) * 1998-10-26 2000-05-04 Ludwig Institute For Cancer Research Use of vegf-c or vegf-d gene or protein to prevent restenosis
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
US7097832B1 (en) * 1999-03-30 2006-08-29 Myocardial Therapeutics, Inc. Intramyocardial injection of autologous bone marrow
US20040131601A1 (en) * 2000-03-30 2004-07-08 Foundry Networks, Inc., A Delaward Corporation Injection of bone marrow-derived cells and medium for angiogenesis
US7125856B1 (en) 1999-04-15 2006-10-24 St. Elizabeth's Medical Center Of Boston, Inc. Angiogenic growth factors for treatment of peripheral neuropathy
EP1183357A2 (de) * 1999-05-20 2002-03-06 Scios Inc. Vaskuläre endothelzellen wachstumsfaktordimere
AU5023300A (en) 1999-05-20 2000-12-12 Scios Inc. Vascular endothelial growth factor variants
US6899731B2 (en) * 1999-12-30 2005-05-31 Boston Scientific Scimed, Inc. Controlled delivery of therapeutic agents by insertable medical devices
AU2001245734A1 (en) * 2000-03-15 2001-09-24 Orbus Medical Technologies Inc. Coating that promotes endothelial cell adherence
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8460367B2 (en) 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
EP1272208B1 (de) 2000-04-12 2011-10-05 VIB vzw Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen
WO2002002148A2 (en) * 2000-06-30 2002-01-10 Collateral Therapeutics, Inc. Dual recombinant gene therapy compositions and methods of use
DE60129229T2 (de) * 2000-08-17 2008-05-08 Ozawa, Keiya Adeno-assoziierte virus-vermittelte übertragung von angiogenesefaktoren
US6953560B1 (en) 2000-09-28 2005-10-11 Advanced Cardiovascular Systems, Inc. Barriers for polymer-coated implantable medical devices and methods for making the same
US6716444B1 (en) 2000-09-28 2004-04-06 Advanced Cardiovascular Systems, Inc. Barriers for polymer-coated implantable medical devices and methods for making the same
AU2002228841C1 (en) 2000-12-07 2006-11-23 Sangamo Biosciences, Inc Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US6663662B2 (en) 2000-12-28 2003-12-16 Advanced Cardiovascular Systems, Inc. Diffusion barrier layer for implantable devices
US20050142130A1 (en) * 2001-01-04 2005-06-30 Roks Antonius J.M. Use of angiotensin-(1-7) for preventing and/or reducing the formation of neointima
DK1399484T3 (da) * 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
EP2311960A3 (de) 2001-08-29 2011-06-01 Genentech, Inc. Bv8-Nukleinsäuren und Polypeptide mit mitogener Aktivität
WO2003020215A2 (en) 2001-08-29 2003-03-13 Regenerx Biopharmaceuticals, Inc. Methods of treating mycocardial event related coditions with thymosin beta 4
US6753071B1 (en) * 2001-09-27 2004-06-22 Advanced Cardiovascular Systems, Inc. Rate-reducing membrane for release of an agent
US20040009937A1 (en) * 2002-01-31 2004-01-15 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
US20050075298A1 (en) * 2002-01-31 2005-04-07 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa
US20040043003A1 (en) * 2002-01-31 2004-03-04 Wei Chen Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions
CA2487410C (en) * 2002-05-30 2015-03-24 Myocardial Therapeutics, Inc. Intramyocardial injection of autologous bone marrow
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060251643A1 (en) * 2002-12-09 2006-11-09 Toolgen, Inc. Regulatory zinc finger proteins
WO2004055156A2 (en) * 2002-12-17 2004-07-01 Technion Research And Development Foundation Ltd. A vegf variant that lacks vegfr-1 binding activity and its use in promotion of re-endothelization and prevention of in-stent restenosis
EP1578801A2 (de) * 2002-12-27 2005-09-28 Domantis Limited Dual-spezifischer einzeldomäne-antikörper welcher spezifisch ist für einen liganden und dessen rezeptor
JP4912144B2 (ja) 2003-03-12 2012-04-11 ジェネンテック， インコーポレイテッド 造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用
CN101277704A (zh) * 2005-04-12 2008-10-01 因特拉迪格姆公司 用于治疗癌症及其它新血管生成疾病的RNAi治疗剂的组合物和方法
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
KR100772424B1 (ko) * 2005-08-05 2007-11-01 박기랑 ⅤＥＧＦ－Ａ，ⅤＥＧＦ－Ｂ，및 ⅤＥＧＦ－Ｃ의 안티센스 ｃＤＮＡ를 함유하는 재조합 아데노-연관 바이러스 및 ⅤＥＧＦＲ 트렁케이티드 솔루블 ｃＤＮＡ를 함유하는 재조합 아데노-연관 바이러스를 포함하는 암의 유전자 치료제
JP2009519011A (ja) * 2005-12-01 2009-05-14 ドマンティス リミテッド インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット
JP2010528647A (ja) * 2007-06-06 2010-08-26 ドマンティス リミテッド ポリペプチド、抗体可変ドメインおよびアンタゴニスト
ES2440751T3 (es) * 2008-10-07 2014-01-30 Boston Scientific Scimed, Inc. Dispositivos médicos para administración de agentes terapéuticos a los lúmenes corporales
CN110760542B (zh) * 2019-11-18 2022-07-26 天津大学 一种共表达znf580和vegf165双基因的质粒及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5240848A (en) * 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5288846A (en) * 1990-10-19 1994-02-22 The General Hospital Corporation Cell specific gene regulators
US5298422A (en) * 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
US5318957A (en) * 1992-09-02 1994-06-07 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating angiogenesis
DE69523163T2 (de) * 1994-07-20 2002-03-07 Kyowa Hakko Kogyo Co., Ltd. Verfahren zur herstellung von stabilisierter getrockeneter carboxyesterase
US5552309A (en) * 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
US5652225A (en) * 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors

Also Published As

Publication number Publication date
CA2265252C (en) 2005-04-19
EP0925360A1 (de) 1999-06-30
EA199900262A1 (ru) 1999-10-28
US6589782B1 (en) 2003-07-08
IL128727A (en) 2007-06-17
DE69726741D1 (de) 2004-01-22
AU4247197A (en) 1998-03-26
CA2265252A1 (en) 1998-03-12
EA004646B1 (ru) 2004-06-24
US6013780A (en) 2000-01-11
NZ334508A (en) 2001-03-30
DE69726741T2 (de) 2004-09-30
JP2001500728A (ja) 2001-01-23
CN1236390A (zh) 1999-11-24
IL128727A0 (en) 2005-11-20
HK1020756A1 (en) 2000-05-19
KR20000068506A (ko) 2000-11-25
US6583276B1 (en) 2003-06-24
WO1998010071A1 (en) 1998-03-12
ES2212127T3 (es) 2004-07-16
AU737898B2 (en) 2001-09-06
EP0925360B1 (de) 2003-12-10

Similar Documents

Publication Publication Date Title
DE69726741D1 (de) Verwendungen von angiogenischer factor vegf145 in der behandlung von kardiovaskulaeren krankheiten
Lee et al. Impaired wound healing and angiogenesis in eNOS-deficient mice
PT749317E (pt) Aplicacoes terapeuticas de produtos dimericos de proteinas bactericidas indutoras da permeabilidade
WO1999040197A3 (en) Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
KR950700995A (ko) 조절 신호인 지방체(oil-body) 단백질 시스-요소(cis-element)(OIL-BODY PROTEIN CIS-ELEMENTS AS REGULATORY SIGNALS)
TR199902818T2 (xx) Be�eri kullan�m i�in antikorlar ve be�eri kullan�m i�in antikorlar olu�turmak i�in y�ntemler.
DE69328685D1 (de) Verfahren zur inaktivierung von bakterien in blutpräparaten mit hilfe von methoxypsoralen
DE69937294D1 (de) Von cyclophilin b abstammende tumorantigen-peptide
JP2002531055A5 (de)
BR9709015A (pt) Quinolina carboxamidas como inbidores de tnf e como inbidores de pde-iv
DE69531332D1 (de) Klonierung und Expression eines Gens, das Bryodin 1 aus Bryonia dioica kodiert
BR0016032A (pt) Colágeno
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
ATE333275T1 (de) Indole-3-propionsäure, ihre salze und ester als arzneimittel
ATE294236T1 (de) Promotor der tie rezeptor protein kinase
FR2805821B1 (fr) Sequences d'acides amines facilitant la penetration d'une substance d'interet a l'interieur des cellules et/ou des noyaux cellulaires
ATE257152T1 (de) N-benzyl-3-indenylaceamidderivative zur behandlung von neoplasia
Ulrich et al. Expression profile of proteins involved in scar formation in the healing process of full‐thickness excisional wounds in the porcine model
ATE287722T1 (de) Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1
DE69510356D1 (de) Anti-sickling beta-globin,zusammensetzung und verfahren zur behandlung von sichelzellanämie
DE60024997D1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
EA200000270A1 (ru) КОМПОЗИЦИИ ДЛЯ ГЕНОТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ ГЕНОВ, КОДИРУЮЩИХ СЕКРЕТИРУЕМЫЕ БЕЛКИ, ТАКИЕ КАК β-ИНТЕРФЕРОН, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
IT1299201B1 (it) Fibroblasti modificati geneticamente e loro uso

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0925360

Country of ref document: EP

REN Ceased due to non-payment of the annual fee